Drugs / SC0062
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06072326 | Jan 2026 → Dec 2027 expected | diabetic kidney disease | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05687890 | May 2023 → Nov 2024 overdue | IgA glomerulonephritis, diabetic kidney disease | Biocity Biopharmaceutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06819826 | Feb 2025 → Dec 2026 expected | IgA glomerulonephritis | Biocity Biopharmaceutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC0062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072326 ↗ |
| Action | Inhibit | “SC0062 is a novel selective endothelin receptor type A antagonist.” PMID 39462310 ↗ Oct 2024 |